Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a...

Descripción completa

Detalles Bibliográficos
Autores principales: Frank, Matthew J., Khodadoust, Michael S., Czerwinski, Debra K., Haabeth, Ole A.W., Chu, Michael P., Miklos, David B., Advani, Ranjana H., Alizadeh, Ash A., Gupta, Neel K., Maeda, Lauren S., Reddy, Sunil A., Laport, Ginna G., Meyer, Everett H., Negrin, Robert S., Rezvani, Andrew R., Weng, Wen-Kai, Sheehan, Kevin, Faham, Malek, Okada, Ami, Moore, A. Holliston, Phillips, Destiny L., Wapnir, Irene L., Brody, Joshua D., Levy, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478738/
https://www.ncbi.nlm.nih.gov/pubmed/32558897
http://dx.doi.org/10.1084/jem.20191712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478738/
https://www.ncbi.nlm.nih.gov/pubmed/32558897
http://dx.doi.org/10.1084/jem.20191712

Ejemplares similares